10-K: Goldenwell Biotech Reports Losses in 2024, Faces Going Concern Uncertainty

Goldenwell Biotech's 2024 10-K filing reveals continued losses, minimal revenue, and substantial doubt about its ability to continue as a going concern.

Summary

• Goldenwell Biotech, Inc. reported its financial results for the year ended December 31, 2024, in its Form 10-K filing.
• The company incurred a net loss of $131,498 in 2024, compared to a net loss of $117,361 in 2023.
• Revenues decreased significantly from $1,836 in 2023 to $139 in 2024.
• The company's accumulated deficit as of December 31, 2024, was $1,359,645.
• Goldenwell Biotech has limited operations and revenues, leading to recurring losses.
• The company's ability to continue as a going concern is dependent on raising capital and achieving profitable operations.
• As of December 31, 2024, the company had cash and cash equivalents of $49,404.
• The company plans to increase sales of its nutraceutical and dietary supplements.
• The company believes it can satisfy its cash requirements through the fiscal year end of December 31, 2024, from its cash of $49,404.
• The company estimates it needs approximately $5,000,000 to complete manufacturing facilities and train its workforce.
• The company relies on exclusive license agreements with Australian Trefoil Health Technologies Pty Ltd and Ji Lin JZY Biotech Inc.
• The company's internal control over financial reporting was not effective as of December 31, 2024, due to a lack of independent directors and inadequate segregation of duties.

Sentiment

Score: 3

Explanation: The document presents a negative outlook due to recurring losses, minimal revenue, and uncertainty about the company's ability to continue as a going concern. The company's reliance on raising additional capital and the ineffectiveness of its internal control over financial reporting further contribute to the negative sentiment.

Positives

• The company has exclusive license agreements for its technology and packaging designs.
• The company plans to increase sales of its products.
• The company believes it can satisfy its cash requirements through the fiscal year end of December 31, 2024, from its cash of $49,404.
• As of December 31, 2024, the company had a working capital balance of $222,332.

Negatives

• The company incurred a net loss of $131,498 in 2024.
• Revenue decreased significantly to $139 in 2024.
• The company's accumulated deficit reached $1,359,645.
• The company's auditors have raised substantial doubt about the company's ability to continue as a going concern.
• The company's internal control over financial reporting was not effective as of December 31, 2024.
• The company needs approximately $5,000,000 to complete manufacturing facilities and train its workforce.

Risks

• The company's ability to continue as a going concern is uncertain.
• The company's success depends on raising additional capital.
• The company faces competition in the nutraceutical and dietary supplements market.
• The company's internal control over financial reporting is not effective.
• The company has limited operations and revenues.
• The company relies on exclusive license agreements, which could be a risk if the agreements are terminated or not renewed.
• The company's common stock may be subject to penny stock regulations, which could restrict the ability of broker-dealers to sell the stock.

Future Outlook

The company plans to increase the sales of its products and believes it can satisfy its cash requirements through the fiscal year end of December 31, 2024, from its cash of $49,404. The company estimates it needs approximately $5,000,000 to complete manufacturing facilities and train its workforce.

Management Comments

• Management believes that the continuing financial support from the existing shareholders and external financing will provide the additional cash to meet our obligations as they become due.

Industry Context

The company operates in the nutraceutical and dietary supplements industry, which is highly competitive. The company competes with traditional, offline consumer resources, and with online providers of consumer ratings, reviews and referrals.

Comparison to Industry Standards

• It is difficult to compare Goldenwell Biotech to industry standards due to its early stage and limited operations.
• Larger, more established nutraceutical companies typically have significantly higher revenues and lower net losses.
• For example, companies like Herbalife Nutrition and Amway have billions in revenue and positive net income.
• Goldenwell Biotech's reliance on exclusive license agreements is a common practice in the biotech industry, but the company's limited financial resources make it more vulnerable to risks associated with these agreements.

Corporate Governance

Related Party Transactions

• During the years ended December 31, 2024 and 2023, the Company received a loan of $0 and $75,588 from the Company's CEO and Director, respectively.
• The related party loan of $20,000 received on December 21, 2022, has a five-year term and remained outstanding as of December 31, 2024.
• As of December 31, 2024 and 2023, the Company owed $95,588 and $95,588, respectively, to its CEO and Director.

Stakeholder Impact

• Shareholders may experience dilution if the company raises additional capital through equity offerings.
• Employees may be affected by the company's financial difficulties and uncertainty about its ability to continue as a going concern.
• The company's suppliers and creditors may be at risk if the company is unable to meet its financial obligations.

Next Steps

• The company plans to increase the sales of its products.
• The company plans to raise additional funds through debt or equity offerings.
• The company needs to construct manufacturing facilities, which includes locating a site, installing a workshop and setting up equipment.
• The company's workforce will need to be trained.

Key Dates

Keywords

biotech, financial results, going concern, nutraceutical, dietary supplements, license agreements, internal control, losses, revenue, capital, Goldenwell Biotech